Assay Advancements: Exploring Varied Assays for Thyroid-Stimulating Hormone Measurement in Subclinical Hypothyroidism Diagnosis in Riyadh, Saudi Arabia  

作　　者：Qumasha Alobaid Sumayah Aljenedil Waleed Altamimi Khalid Alsumaily Qumasha Alobaid;Sumayah Aljenedil;Waleed Altamimi;Khalid Alsumaily(Biochemistry Laboratory Department, King Abdulaziz Medical Center of National Guard Hospital, Riyadh, Saudi Arabia;Biochemistry Laboratory Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia;Biochemistry Laboratory Department, King Khalid University Hospital, Riyadh, Saudi Arabia)

机构地区：[1]Biochemistry Laboratory Department, King Abdulaziz Medical Center of National Guard Hospital, Riyadh, Saudi Arabia [2]Biochemistry Laboratory Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia [3]Biochemistry Laboratory Department, King Khalid University Hospital, Riyadh, Saudi Arabia

出　　处：《Open Journal of Medicinal Chemistry》2024年第4期45-56,共12页药物化学期刊(英文)

摘　　要：Thyroid-stimulating hormone (TSH) assay is considered a decisive diagnostic method for thyroid disorders. The lack of different TSH immunoassay standardization often leads to misdiagnosis of subclinical hypothyroidism (SCH). This study aims to differentiate between two analytical platforms for TSH measurement, namely Abbott Laboratories and Snibe Diagnostics. This study employed 173 thyroid profile samples to detect SCH. Initially, the sample was run on Abbott and then by Snibe immunoassay. Statistical analysis showed a significant difference of 0.87 mIU/L (P < 0.001) between the TSH values of the two assays. The proposed study corroborates with previous literature by manifesting notable differences in the TSH measurements of two different assays. The findings revealed some insights regarding the differences between the two assays, which conclude that the diagnosis of SCH requires vigilance because of inadequate assay standardization. Thus, future research involving larger cohorts with standardization efforts is imperative to improve the reliability of TSH measurements using different analytical platforms.Thyroid-stimulating hormone (TSH) assay is considered a decisive diagnostic method for thyroid disorders. The lack of different TSH immunoassay standardization often leads to misdiagnosis of subclinical hypothyroidism (SCH). This study aims to differentiate between two analytical platforms for TSH measurement, namely Abbott Laboratories and Snibe Diagnostics. This study employed 173 thyroid profile samples to detect SCH. Initially, the sample was run on Abbott and then by Snibe immunoassay. Statistical analysis showed a significant difference of 0.87 mIU/L (P < 0.001) between the TSH values of the two assays. The proposed study corroborates with previous literature by manifesting notable differences in the TSH measurements of two different assays. The findings revealed some insights regarding the differences between the two assays, which conclude that the diagnosis of SCH requires vigilance because of inadequate assay standardization. Thus, future research involving larger cohorts with standardization efforts is imperative to improve the reliability of TSH measurements using different analytical platforms.

关 键 词：Immunoassays Subclinical Hypothyroidism Thyroid Stimulating Hormone 

分 类 号：R58[医药卫生—内分泌]